MENQUADFI SOLUTION FOR INJECTION

INJECTION, SOLUTION

**Posology and method of administration** Posology Primary vaccination: - Individuals 12 months of age and older: One single dose (0.5 mL). Booster vaccination: - A single 0.5 mL dose of MenQuadfi may be used to boost subjects who have previously received a meningococcal vaccine containing the same serogroups (see section Pharmacodynamic properties – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). - Long-term antibody persistence data following vaccination with MenQuadfi are available up to 7 years after vaccination (see sections Special warnings and precautions for use and Pharmacodynamic properties – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). - There are no data available to indicate the need for or timing of a booster dose of MenQuadfi (see section Pharmacodynamic properties – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). _Other paediatric population_ The safety and immunogenicity of MenQuadfi in individuals under 12 months of age have not yet been established. Method of administration For intramuscular injection only, preferably in the deltoid region or anterolateral thigh depending on the recipient's age and muscle mass. For instructions on handling of the vaccine before administration, see section Special precautions for disposal and other handling – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.